Camden's client Inovio Pharmaceuticals, the inovative American biotech is Added To Russell Global, Russell 2000® and Russell Microcap® Indexes

Inovio Shares Enter No. 1 U.S. Equity Index for Asset Benchmarking

PLYMOUTH MEETING, PA – July 1, 2014 – Inovio Pharmaceuticals, Inc. (NYSE MKT: INO)
announced that it has been added to the Russell Global, Russell 2000 and Russell
Microcap Indexes. Each June, Russell realigns its family of global equity indexes to
reflect market changes in the past year. Approximately $5.2 trillion in assets are
currently benchmarked to Russell Indexes.

Many investors use mutual funds or exchange-traded funds based on the Russell
Indexes as a way to gain exposure to certain portions of the U.S. stock market.
Russell's index design has led to more assets benchmarked to its U.S. index family
than all other U.S. equity indexes combined. The most well-known index of the series
is the Russell 2000, which tracks US small-cap stocks.
Inclusion in these indexes is based upon market capitalization and other market
factors relating to a company and its stock. Membership in these indexes is updated
annually and remains in place for one year.
Dr. J. Joseph Kim, Inovio’s President and CEO, said, “We are pleased to meet the
requirements for inclusion in these Russell Indexes. This inclusion reflects
Inovio’s accomplishments in advancing its promising DNA immunotherapy science and
clinical programs as well as in partnering important products. Being part of these
indexes will increase awareness of Inovio among investors in the U.S. and globally,
and increase institutional ownership of Inovio stock through passive index fund

About Russell

Russell Investments is a global asset manager and one of only a few firms that
offers actively managed multi-asset portfolios and services that include advice,
investments and implementation. Russell stands with institutional investors,
financial advisors and individuals working with their advisors—using the firm's core
capabilities that extend across capital market insights, manager research, portfolio
construction, portfolio implementation and indexes to help each achieve their
desired investment outcomes.

About Inovio Pharmaceuticals, Inc.

Inovio is revolutionizing vaccines to prevent and treat today's cancers and
challenging infectious diseases. Its SynCon® DNA immunotherapies, in combination
with its proprietary electroporation delivery, are generating best-in-class immune
responses, with therapeutic T-cell responses exceeding other technologies in terms
of magnitude, breadth, and response rate. Human data to date have shown a favorable
safety profile. Inovio's lead vaccine, a therapeutic against HPV-caused pre-cancers
and cancers, is in phase II. Other phase I and preclinical programs target prostate,
breast, and lung cancers as well as HIV, influenza, malaria and hepatitis. Partners
and collaborators include Roche, the University of Pennsylvania, NIH, HIV Vaccines
Trial Network, National Cancer Institute, U.S. Military HIV Research Program, US
Dept. of Homeland Security, and University of Manitoba. More information is
available at

Investors: Bernie Hertel, Inovio Pharmaceuticals, 858-410-3101,
Media: Jeff Richardson, Inovio Pharmaceuticals, 267-440-4211,